Report Description of the APAC Epilepsy Therapeutics Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for APAC Epilepsy Therapeutics Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the APAC Epilepsy Therapeutics Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

APAC Epilepsy Therapeutics Market Analysis Executive Summary

Epilepsy is a common condition that affects the brain and causes frequent seizures. Seizures are bursts of electrical activity in the brain that temporarily affect how it works. They can cause a wide range of symptoms. Epilepsy can start at any age, but usually starts either in childhood or in people over 60. It's often lifelong, but can sometimes get slowly better over time.

Market Size and Key Findings

The APAC Epilepsy Therapeutics Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 4.01% during the forecast period.

The epilepsy therapeutics market in APAC has the potential to grow by USD 296.44 million during 2020-2028, and the markets growth momentum will accelerate at a CAGR of 4.01%.



Market Dynamics

Market Growth Drivers Analysis

The market is driven by the high unmet medical need, increase in patient population, and rising awareness. In addition, high unmet medical need is anticipated to boost the growth of the market as well. The market is driven by the increase in the patient population.

Market Restraints

The technological advancements in non-invasive neuromodulation and seizure management devices may impede market growth.

COVID-19 impact on APAC Epilepsy Therapeutics Market

The COVID-19 pandemic continues to transform the growth of various industries; however, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. COVID-19 will have at Par impact on the Epilepsy Therapeutic market in APAC.

Competitive Landscape

Key Players

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading epilepsy therapeutic market in APAC vendors that include Bausch Health Companies Inc., BIAL - PORTELA & CA SA, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., SanofiSA, Sunovion Pharmaceuticals Inc., UCB SA, and Zogenix Inc. Also, the epilepsy therapeutic market in APAC analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

Products in Pipeline

Second generation AEDs with newer mechanisms of action, such as Keppra (levetiracetam), Zonegran (zonisamide) and Vimpat (lacosamide), have signaled a shift in the last decade with improved tolerability and efficacy. Recent approvals, including Fycompa (perampanel) and Trobalt (retigabine) have continued this trend by focusing on new molecular targets.

Notable Recent Deals

• The Epilepsy Foundations Shark Tank Competition seeks to advance innovative ideas in epilepsy seizure treatment and care. The winners will use their prize to accelerate their innovation to the next phase of development and closer to being accessible to people living with epilepsy. In total, 35 individuals or teams entered the competition from across the United States and 8 countries throughout the world. From this pool, 5 teams were chosen as finalists. The finalists presented on May 24, 2019, at the 2019 Antiepileptic Drug & Device (AEDD) Trials XV Conference in Florida.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

At the 65th WHO Western Pacific Regional Committee meeting (65th WPRCM),which was held in Manila, Philippines, October 1317, 2014, a representative of the IBE (Chairman of the ILAE/IBE Research Advocacy Task Force) made a statement to call for a WHO Western Pacific Strategic Action for Epilepsy: through coordinated efforts at country level designed to:

• assess the size of the epilepsy burden and related specificities and needs;


• (ii) introduce and implement national epilepsy programs and services in accordance with international human rights norms and standards;


• (iii) minimize the gaps in diagnosis and treatment, by addressing inequalities in care and facilitating access to affordable medicines and other treatments;


• (iv) enact legislation to protect the rights of people with epilepsy; and


• (v) establish awareness initiatives to educate the public about the nature of the disease and thereby remove stigmatization. The response and effects of the call, however, were not satisfactory.

 

[wpforms id="38613"]